John Hunt
Family Medicine · Malden, MONPI 1508881533
Payments from drug & device makers
Across 113 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$561
- AstraZeneca$325
- Boehringer Ingelheim$205
- Amarin Pharma, Inc.$177
- GSK$154
- Sanofi-aventis U.S. LLC$111
- plus $605 from 15 others
What the payments were for
- Food & beverage$2,10098%
- Education$382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $561 |
| AstraZeneca | 16 | $325 |
| Boehringer Ingelheim | 12 | $205 |
| Amarin Pharma, Inc. | 15 | $177 |
| GSK | 12 | $154 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Amgen | 2 | $107 |
| Medtronic | 1 | $87 |
| Johnson & Johnson | 4 | $72 |
| Pfizer | 5 | $70 |
| Abbott | 3 | $67 |
| Astellas Pharma US Inc | 3 | $43 |
| Eisai Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Merck | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,138 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $95,618 |
| RybelsusSemaglutide | 70 | $84,931 |
| JanuviaSitagliptin Phosphate | 98 | $68,670 |
| FarxigaDapagliflozin Propanediol | 54 | $49,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $48,184 |
| OzempicSemaglutide | 48 | $47,956 |
| JardianceEmpagliflozin | 70 | $45,166 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $39,112 |
| LinzessLinaclotide | 61 | $38,495 |
| MounjaroTirzepatide | 32 | $35,492 |
| VascepaIcosapent Ethyl | 70 | $30,754 |
| TrulicityDulaglutide | 23 | $27,117 |
| TradjentaLinagliptin | 25 | $24,977 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,101 | $24,697 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $19,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $561 | $132,887118 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Glyxambi | $205 | $97,554149 claims |
| PfizerEliquis | $70 | $95,618123 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $154 | $70,290128 claims |
| MerckJanuvia | $11 | $68,67098 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $325 | $66,57891 claims |
| Lilly USA, LLCMounjaro, Trulicity | $29 | $62,60955 claims |
| Johnson & JohnsonXarelto | $72 | $17,42624 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $13,13518 claims |
| Redhill Biopharma Inc.Movantik | $18 | $6,18015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Malden
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.